These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34972256)

  • 21. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease.
    Yassi N; Hilal S; Xia Y; Lim YY; Watson R; Kuijf H; Fowler C; Yates P; Maruff P; Martins R; Ames D; Chen C; Rowe CC; Villemagne VL; Salvado O; Desmond PM; Masters CL
    J Alzheimers Dis; 2020; 73(3):897-907. PubMed ID: 31884485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
    Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
    Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
    Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
    J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.
    Elman JA; Panizzon MS; Gustavson DE; Franz CE; Sanderson-Cimino ME; Lyons MJ; Kremen WS;
    Biol Psychiatry; 2020 May; 87(9):819-828. PubMed ID: 32067693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
    Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
    Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
    Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
    Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations of Subsyndromal Symptomatic Depression with Cognitive Decline and Brain Atrophy in Elderly Individuals without Dementia: A Longitudinal Study.
    Zhang Z; Wei F; Shen XN; Ma YH; Chen KL; Dong Q; Tan L; Yu JT;
    J Affect Disord; 2020 Sep; 274():262-268. PubMed ID: 32469814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.
    Clark LR; Racine AM; Koscik RL; Okonkwo OC; Engelman CD; Carlsson CM; Asthana S; Bendlin BB; Chappell R; Nicholas CR; Rowley HA; Oh JM; Hermann BP; Sager MA; Christian BT; Johnson SC
    Alzheimers Dement; 2016 Jul; 12(7):805-14. PubMed ID: 26806386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer's Disease Pathology in Women versus Men?
    Sundermann EE; Biegon A; Rubin LH; Lipton RB; Landau S; Maki PM;
    J Alzheimers Dis; 2017; 56(3):947-957. PubMed ID: 28106548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.